Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and <i>DDX41</i> Mutation: Mayo Clinic Experience
Ahmad Nanaa(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Dragan Jevremović(Mayo Clinic in Arizona), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), James M. Foran(Memorial Sloan Kettering Cancer Center), Mrinal M. Patnaik(Mayo Clinic), Patricia T. Greipp(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Rong He(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Phuong L. Nguyen(St. Jude Children's Research Hospital), Lisa Z. Sproat(Mayo Clinic Hospital), Naseema Gangat(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Aref Al‐Kali(Mayo Clinic)
Cited by 1
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
|The Journal of Experimental Medicine|2004|1.8k